UNSPSC 51183607: Insulin aspart

This classification denotes a therapeutic insulin with the molecular formula C256H381N65O79S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D933668QVX, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG.

UNSPSC 51183607 Insulin aspart, a Commodity code, encompasses insulin aspart pharmaceutical products that state and local governments procure through cooperative purchasing arrangements and direct pharmaceutical supply contracts. State and local health agencies, correctional facilities, and social-service departments acquire insulin aspart as part of broader pharmaceutical procurement initiatives to support patient care across government health systems. The code reflects sourcing of a specific insulin formulation rather than a broad therapeutic category, with procurement typically embedded in multistate or single-jurisdiction pharmaceutical supply agreements that specify National Drug Codes, dosage strengths, packaging configurations, and delivery through authorized pharmaceutical wholesalers.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. Under that RFP, vendors supply insulin aspart and related pharmaceuticals through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products required to be available by May 15, 2026 and contracts effective July 1, 2026. Awarded contracts run two years for new responders with optional extensions, and evaluation emphasizes price competitiveness (75 percent weight), fixed pricing stability (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format compliance (5 percent). Vendors must hold $5 million commercial general liability coverage, maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place, certify cGMP and DSCSA compliance, and accept a 3 percent administrative fee on all contract purchases.